ZILLOW GROUP, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ZILLOW GROUP, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.08B | Feb 15, 2018 |
| FY2017 | Dec 31, 2016 | $846.59M | Feb 15, 2018 |
| FY2017 | Dec 31, 2015 | $644.68M | Feb 15, 2018 |
| FY2016 | Dec 31, 2014 | $325.89M | Feb 7, 2017 |
| FY2015 | Dec 31, 2013 | $197.55M | Feb 12, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.58B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.24B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.95B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.96B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $2.13B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.62B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $2.74B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $1.33B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.08B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $846.59M | Feb 21, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.92B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.71B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $1.52B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.59B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $1.81B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.37B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.20B | Feb 10, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($112.00M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($158.00M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($101.00M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | ($528.00M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($162.00M) | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | ($305.36M) | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | ($119.86M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | ($94.42M) | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | ($220.44M) | Feb 21, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.00M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($197.00M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($270.00M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($93.00M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $239.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $109.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | ($247.49M) | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | ($128.98M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | ($161.87M) | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | ($192.85M) | Feb 21, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $607.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $585.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $560.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $498.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $421.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $324.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $350.92M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $410.82M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $319.99M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $255.58M | Feb 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $368.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $428.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $354.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $4.50B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | ($3.18B) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $423.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | ($612.17M) | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $3.85M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $258.19M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $8.65M | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $143.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $135.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $115.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $74.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $85.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $67.04M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $66.05M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $66.73M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $62.06M | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.69B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $5.83B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $6.65B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $6.56B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $10.70B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $7.49B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $6.13B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $4.29B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $3.23B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $3.15B | Feb 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $801.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $981.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $2.13B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $2.08B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $5.35B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $2.74B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $2.70B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.02B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $569.69M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $616.09M | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.88B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $4.85B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $4.53B | Feb 11, 2026 |
| FY2025 | Dec 31, 2022 | $4.48B | Feb 11, 2026 |
| FY2024 | Dec 31, 2021 | $5.34B | Feb 11, 2025 |
| FY2023 | Dec 31, 2020 | $4.74B | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | $3.44B | Feb 15, 2023 |
| FY2021 | Dec 31, 2018 | $3.27B | Feb 10, 2022 |
| FY2020 | Dec 31, 2017 | $2.66B | Feb 12, 2021 |
| FY2019 | Dec 31, 2016 | $2.53B | Feb 19, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.82B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $2.82B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $2.82B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $2.37B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.37B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.98B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.98B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.98B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.93B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $1.92B | Feb 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.86B) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($1.88B) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($1.77B) | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | ($1.61B) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($1.67B) | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | ($1.14B) | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | ($977.14M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | ($671.78M) | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | ($592.24M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($497.04M) | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $768.00M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $1.08B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $1.49B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $1.47B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.32B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.70B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.14B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $651.06M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $352.10M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $243.59M | Feb 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 10, 2022 |